Large B-cell non-Hodgkin lymphoma relapsing with meningeal localization
نویسندگان
چکیده
منابع مشابه
Large B-cell non-Hodgkin lymphoma relapsing with meningeal localization.
A 76-year-old woman presented with diffuse large B-cell non-Hodgkin lymphoma (NHL), stage III A, low-intermediate International Prognostic Index. The disease involved the retroperitoneum, laterocervical, and supraclavicular regions. Bone marrow and other organ sites were negative. She received 5 of 6 planned cycles with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone. One ...
متن کاملEmploying PCR Technique in Assessment of Monoclonality in Large B-cell Non-Hodgkin\'s Lymphoma
Introduction: Most B-cell malignancies are diagnosed based on morphologic and immunohistochemical criteria. Some cases, however, still present a challenge for the pathologist to discriminate between reactive hyperplasia and neoplastic disorders. Molecular techniques can be used as a helpful diagnostic tool in these cases. In this study, we assessed the value of polymerase chain reaction (PCR) t...
متن کاملemploying pcr technique in assessment of monoclonality in large b-cell non-hodgkin's lymphoma
introduction: most b-cell malignancies are diagnosed based on morphologic and immunohistochemical criteria. some cases, however, still present a challenge for the pathologist to discriminate between reactive hyperplasia and neoplastic disorders. molecular techniques can be used as a helpful diagnostic tool in these cases. in this study, we assessed the value of polymerase chain reaction (pcr) t...
متن کاملHodgkin Lymphoma and Anaplastic Variants of Non-Hodgkin Lymphoma
Background and Objectives: Classic Hodgkin lymphoma (CHL), anaplastic large cell lymphoma (ALCL) and some cases of diffuse large B cell lymphoma (DLBCL) have overlapping morphologic features. Since they all represent distinct clinico-pathologic entities, we explored the differential diagnostic impact of immunophenotyping to discriminate between them. Materials and Methods:...
متن کاملDevelopment of DOTA-Rituximab kit formulation to be labeled with 90Y for radioimmunotherapy of B-cell Non-Hodgkin Lymphoma
NHL is the most common hematologic cancer in adults. Rituximab is the FDA approved treatment of relapsed or refractory low grade B-cell Non-Hodgkin Lymphoma (NHL). But patients eventually become resistant to rituximab. Since lymphocytes and lymphoma cells are highly radiosensitive, low grade NHL that has relapsed or refractory to standard therapy is treated by RIT in which a beta-emitting radio...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Blood
سال: 2012
ISSN: 0006-4971,1528-0020
DOI: 10.1182/blood-2011-11-390914